button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

es-BC - TNBC - NA - all population breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 ---
versus placebo
durvalumab alone vs. placebo 1 ---
pembrolizumab alone vs. placebo 1 ---
versus placebo plus SoC
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo plus SoC 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		--

es-BC - TNBC - NA - PDL1 positive breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - PDL1 positive

versus placebo plus SoC
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo plus SoC 1 ---

mBC - Triple negative (TNBC) - 1st Line (L1) breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1)

mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
versus Standard of Care (SoC)
atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) 1 -532 [-1173; 108] /10000
255/451 vs. 279/451		-443 [-948; 62] /10000
358/451 vs. 378/451		-
atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-

mBC - TNBC - L1 - PDL1 positive breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - PDL1 positive

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 2 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
versus Standard of Care (SoC)
atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) 1 -897 [-1908; 113] /10000
94/185 vs. 110/184		-1073 [-1882; -264] /10000
138/185 vs. 157/184		-
atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		NaN [NaN; NaN] /10000
0/0 vs. 0/0		-

mBC-Triple negative (TNBC) - 2nd Line (L2) breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2)

mBC - TNBC - L2 - all population breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2) mBC - TNBC - L2 - all population

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 -281 [-815; 253] /10000
266/312 vs. 273/310		2041 [1398; 2683] /10000
272/312 vs. 207/310		-

mBC - TNBC - L2 - PDL1 positive breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2) mBC - TNBC - L2 - PDL1 positive

versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 2 -636 [-1279; 7] /10000
171/203 vs. 183/202		1491 [736; 2246] /10000
179/203 vs. 148/202		-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons